Fidelity Investments’s Palvella Therapeutics PVLA Stock Holding History

Fidelity Investments’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.8M	Sell	214,841 -967	-0.4%	-$117K	﹤0.01%	1690
2026 Q1	$26.9M	Sell	215,808 -15,952	-7%	-$1.66M	﹤0.01%	1668
2025 Q4	$24.3M	Buy	231,760 +121,314	+110%	+$10.3M	﹤0.01%	1705
2025 Q3	$6.92M	Buy	110,446 +110,344	+108,180%	+$4.92M	﹤0.01%	2126
2025 Q2	$2.3K	Buy	+102	New	+$2.39K	﹤0.01%	4838
2023 Q3	–	Sell	-572	Closed	-$12.3K	–	5562
2023 Q2	$7.57K	Sell	572 -1,338	-70%	-$81.1K	﹤0.01%	4238
2023 Q1	$149K	Buy	1,910 +252	+15%	+$29.2K	﹤0.01%	3071
2022 Q4	$138K	Buy	1,658 +90	+6%	+$7.23K	﹤0.01%	3108
2022 Q3	$144K	Hold	1,568	–	–	﹤0.01%	3155
2022 Q2	$235K	Hold	1,568	–	–	﹤0.01%	3087
2022 Q1	$380K	Buy	+1,568	New	+$412K	﹤0.01%	3071
2020 Q4	–	Sell	-16	Closed	-$3K	–	4347
2020 Q3	$3K	Buy	16 +11	+220%	+$2.5K	﹤0.01%	3432
2020 Q2	$1K	Buy	+5	New	+$1.17K	﹤0.01%	3510

Other funds holding PVLA

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Fidelity Investments's PVLA Position: Q2 2026 in Review

Fidelity Investments reduced its Palvella Therapeutics (PVLA) stake by 0.45% in Q2 2026, selling an estimated $117K and leaving 214,841 shares worth $32.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1690.

Fidelity Investments first reported a position in PVLA in Q2 2020 and has held it in 13 quarters since. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

Fidelity Investments held 214,841 shares of Palvella Therapeutics worth $32.8M as of Q2 2026.
Fidelity Investments sold 967 Palvella Therapeutics shares in Q2 2026, an estimated $117K.
Palvella Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #1690 holding.
Fidelity Investments first reported a position in Palvella Therapeutics in Q2 2020 and has held it in 13 quarters since.
197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.